375 related articles for article (PubMed ID: 36331504)
1. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
3. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
4. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
5. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
[TBL] [Abstract][Full Text] [Related]
6. Retrospective review of Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrate for reversal of DOAC-Associated Intracranial Hemorrhage.
Troyer C; Nguyen W; Xie A; Wimer D
J Thromb Thrombolysis; 2023 Jan; 55(1):149-155. PubMed ID: 36355324
[TBL] [Abstract][Full Text] [Related]
7. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
8. Resuming anticoagulants after anticoagulation-associated intracranial haemorrhage: systematic review and meta-analysis.
Zhou Z; Yu J; Carcel C; Delcourt C; Shan J; Lindley RI; Neal B; Anderson CS; Hackett ML
BMJ Open; 2018 May; 8(5):e019672. PubMed ID: 29764874
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
10. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
[TBL] [Abstract][Full Text] [Related]
12. A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage.
Berger K; Santibañez M; Lin L; Lesch CA
J Intensive Care Med; 2020 Nov; 35(11):1203-1208. PubMed ID: 30983472
[TBL] [Abstract][Full Text] [Related]
13. Incidence of thromboembolic events following administration of four-factor prothrombin complex concentrate (4F-PCC) for oral anticoagulation reversal.
Makhoul T; Kelly G; Kersten B; Nadler M; Zammit CG; Jones CMC; Scott R; Acquisto NM
Thromb Res; 2020 Oct; 194():158-164. PubMed ID: 32788109
[TBL] [Abstract][Full Text] [Related]
14. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
[TBL] [Abstract][Full Text] [Related]
15. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series.
Bradshaw PG; Keegan S; Foertsch M; Yang GL; Ngwenya LB; Srinivasan V
J Thromb Thrombolysis; 2022 Aug; 54(2):295-300. PubMed ID: 35507109
[TBL] [Abstract][Full Text] [Related]
16. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
17. Safety and effectiveness of Factor Eight Inhibitor Bypassing Activity for direct oral anticoagulant-related hemorrhage reversal.
Engelbart JM; Zepeski A; Galet C; Policeni B; Skeete DA; Faine BA
Am J Emerg Med; 2019 Feb; 37(2):214-219. PubMed ID: 29802004
[TBL] [Abstract][Full Text] [Related]
18. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
19. Intravenous Thrombolysis for Acute Ischemic Stroke in Patients With Recent Direct Oral Anticoagulant Use: A Systematic Review and Meta-Analysis.
Ghannam M; AlMajali M; Galecio-Castillo M; Al Qudah A; Khasiyev F; Dibas M; Ghazaleh D; Vivanco-Suarez J; Morán-Mariños C; Farooqui M; Rodriguez-Calienes A; Koul P; Roeder H; Shim H; Samaniego E; Leira EC; Adams HP; Ortega-Gutierrez S
J Am Heart Assoc; 2023 Dec; 12(24):e031669. PubMed ID: 38108256
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation medication in nontraumatic intracranial hemorrhage survivors with atrial fibrillation.
Wang X; Wen D; Chen Y; You C; Ma L
J Thromb Thrombolysis; 2023 Jul; 56(1):1-11. PubMed ID: 37022508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
